stockmarketproxy
/
BBIONasdaq SEC EDGAR

BridgeBio Pharma, Inc.

Pharmaceutical Preparations·PALO ALTO, CA·FY end 12/31·CIK 1743881
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$502.1M$221.9M$9.3M$77.6M$69.7M
Gross Profit——————
Operating Income-$523.4M-$593.0M-$607.4M-$512.2M-$576.6M
Net Income——————
Operating CF-$445.9M-$520.7M-$527.7M-$419.5M-$497.9M
Capex$1.1M$933.0K$1.3M$4.8M$13.2M
Free Cash Flow-$447.0M-$521.7M-$529.0M-$424.3M-$511.2M
Buybacks$48.3M—$0$0$200.0M
Dividends——————
Gross Margin——————
Operating Margin-104.2%-267.2%-6528.8%-659.6%-827.1%
Net Margin——————
FCF Margin-89.0%-235.1%-5686.6%-546.5%-733.2%
R&D / Revenue90.0%228.2%4898.5%514.5%646.9%
Effective Tax-0.1%-0.2%———
Debt / Equity-0.96-0.30-0.33-0.34-0.60
Buybacks / FCF-10.8%—0.0%0.0%-39.1%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
BBIO
37:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
BBIO
$15M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
BBIO
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%